FDA批准Regeneron的RNAi药Livsayis用于全身性重症肌无力
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
美国FDA于2026年11月18日批准Livsayis(cemdisiran)用于治疗成人AChR抗体阳性全身性重症肌无力,这是Regeneron首款上市的RNA干扰疗法,全年标价41万美元,每年皮下注射四次。该药由Alnylam研发后授权给Regeneron,将与AstraZeneca和Argenx的同类C5靶向药物竞争,分析师预计早期采用较审慎。
RNAi疗法首次获批用于自身免疫疾病,原文给出定价、给药频率及分析机构对早期采用的判断。
An article from
Dive Brief
The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
Published Nov. 19, 2026
Dive Brief:
- The Food and Drug Administration on Wednesday approved a first-of-its-kind medicine Regeneron Pharmaceuticals developed for the autoimmune disease generalized myasthenia gravis.
- Called Livsayis, the drug is an “RNA interference” therapy that thwarts production of a protein, C5, implicated in the errant immune response driving the condition. It was discovered by Alnylam Pharmaceuticals and later licensed to Regeneron in 2019 as part of a broad, RNAi-focused partnership. A year’s supply has a list price of $410,000, according to a Regeneron spokesperson.
- The FDA clearance sanctions treatment for adult patients with the most common, “AChR antibody-positive” form of myasthenia gravis. Livsayis will now compete with multiple other marketed therapies, among them a popular Argenx medicine and a few from AstraZeneca that target C5 in different ways. Adoption is likely to be “measured at first,” wrote RBC Capital Markets analyst Brian Abrahams.
Dive Insight:
Wednesday’s approval is a step forward for Regeneron as well as the RNAi technology Livsayis is built on.
Prior to Livsayis’ clearance, eight RNAi medicines had gotten to market, the majority of which are sold by Alnylam and predominantly used to treat rare diseases. Livsayis is the first to win approval for an autoimmune condition, a reflection of the technology’s maturity and potential to become a more established form of drugmaking alongside small molecules and antibodies.
Livsayis also traveled a winding development path. Alnylam first aimed it at a different autoimmune condition called paroxysmal nocturnal hemoglobinuria that’s treated with C5-targeting drugs. It didn’t show enough in early testing as a monotherapy, leading to a strategic shift toward a combination approach as well as studies in other inflammatory conditions like myasthenia gravis.
That drug, formerly known as cemdisiran, is now a part of Regeneron’s future. The big biotech is currently absorbing the impact of growing biosimilar competition for its flagship eye medication, Eylea, and looking ahead to when another top moneymaker, the anti-inflammatory treatment Dupixent, loses patent protection. Livsayis is one way for Regeneron to branch out in immunology while awaiting readouts for other key programs, like a new kind of blood thinning drug and an RNAi therapy for a common liver disease.
Regeneron bills the drug as a longer-lasting, more convenient alternative to existing medications for myasthenia gravis, which causes debilitating muscular weakness. It’s administered via a subcutaneous injection four times a year. By comparison, a newly approved AstraZeneca drug, Klygefa, is given once-weekly.
Still, the sales projections for Livsayis, at least initially, are the subject of debate among Wall Street analysts. After speaking with a few treating physicians, RBC analyst Abrahams contended that Regeneron is staring at a “relatively challenging launch environment” against “well-entrenched products.” Those doctors “would like to hear more from their colleagues on its use and potential [side effect] profile before adopting it more widely,” he wrote.
The drug’s dosing edge “could serve as an advantage over time,” Abrahams added, but “we do not believe expectations for the launch are that high or that cemdisiran’s success is core to the [Regeneron thesis].”
TD Cowen analyst Tyler Van Buren is more optimistic, writing on Thursday that the drug's “best-in-class efficacy” and dosing advantage should drive uptake, particularly in patients who switch from one therapy to another.
“The market is expanding,” Van Buren wrote. He's projecting $1.5 billion in peak annual sales.
Alnylam will get a $25 million milestone payment tied to Livsayis’ approval and is eligible for sales royalties.
来源:BioPharma Dive · biopharmadive.com